Financial Data and Key Metrics Changes - In Q4 2020, total revenues were $170 million, comparable to Q3 2020, but a 16% decline year-over-year due to COVID impacts [12][26][31] - GAAP gross margin for Q4 was 27%, while non-GAAP gross margin improved to 28%, up two percentage points from Q3 2020 [27][28] - GAAP net loss for Q4 was $26 million or $0.66 per diluted share, compared to a non-GAAP net loss of $2 million or $0.04 per diluted share [31] Business Line Data and Key Metrics Changes - Medical segment revenues in Q4 were $136 million, while Industrial segment revenues were $34 million [25] - Strong sales in the Medical segment were noted for CT tubes, while other medical imaging products continued to decline [14] - Industrial segment sales were down year-over-year, but early signs of recovery were observed in nondestructive testing verticals [21] Market Data and Key Metrics Changes - Q4 revenues were geographically distributed as follows: $64 million in the Americas, $55 million in EMEA, and $51 million in APAC [26] - The China market represented 11% of total revenues in FY 2020, with strong sales of CT systems by local manufacturers [22][23] Company Strategy and Development Direction - The company aims to accelerate organic growth and improve operating margins through operational transformation, referred to as Varex 2.0 [43][44] - Focus on innovation with investments in R&D, particularly in Photon counting detectors and Nanotube x-ray sources [45] - A new capital structure has been established to enhance liquidity and flexibility [10][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth as the economy recovers from COVID impacts, with expectations for increased demand for X-ray imaging equipment [43][44] - The company is shifting to quarterly guidance to better reflect business performance in the current uncertain environment [41] Other Important Information - The company completed the closure of its Santa Clara facility ahead of schedule, expected to yield $28 million in annual cost savings [10][37] - Cash flow from operations was negative $12 million for Q4 but positive $13 million for the full fiscal year [33] Q&A Session Summary Question: Trends in Industrial business amid COVID resurgence - Management noted that the Industrial business is recovering at different rates across various verticals, with strength in electronics and battery inspection [50][53] Question: Status of the China market - Management confirmed that the China market has returned to pre-COVID levels, with ongoing investments in healthcare [54][55] Question: Operating expenses and guidance for Q1 - Management indicated a reduction in operating expenses to $44 million to $45 million for Q1, down from $48 million in Q4 [58] Question: Revenue guidance range for Q1 - The company provided a revenue guidance range of $160 million to $180 million for Q1, reflecting uncertainties due to COVID [42][62] Question: Nanotube technology commercialization timeline - Management expects it will take 2-3 years for the new Nanotube technology to reach the market [100] Question: Cash flow expectations for next year - Management anticipates being cash flow breakeven after the next quarter, contingent on cost reductions and recovery [102]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 _____________ ...

Varex Imaging Corporation (NASDAQ:VREX) Q3 2020 Earnings Conference Call August 12, 2020 5:00 PM ET Company Representatives Sunny Sanyal - President, Chief Executive Officer Sam Maheshwari - Chief Financial Officer Clarence Verhoef - Retiring Chief Financial Officer Howard Goldman - Director of Investor Relations Conference Call Participants Larry Solow - CJS Securities Anthony Petrone - Jefferies Suraj Kalia - Northland Security Jim Sidoti - Sidoti & Company Mark Strouse - JP Morgan Operator Greetings! And ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ____________ ...

Varex Imaging Corporation (NASDAQ:VREX) Q2 2020 Earnings Conference Call May 12, 2020 5:00 PM ET Company Representatives Sunny Sanyal - President, Chief Executive Officer Clarence Verhoef - Chief Financial Officer Howard Goldman - Director of Investor Relations Conference Call Participants Anthony Petrone - Jefferies Larry Solow - CJS Securities Suraj Kalia - Oppenheimer Mark Strouse - JP Morgan Jim Sidoti - Sidoti & Company Operator Greetings! And welcome to Varex Imaging Corporation, Second Quarter Fiscal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 3, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 __________ ...

Varex Imaging Corporation (NASDAQ:VREX) Q1 2020 Earnings Conference Call February 11, 2020 5:00 PM ET Company Participants Howard Goldman - Director of IR Sunny Sanyal - President and CEO Clarence Verhoef - CFO Conference Call Participants Anthony Petrone - Jefferies Larry Solow - CJS Securities Suraj Kalia - Oppenheimer Mark Strouse - JP Morgan Jim Sidoti - Sidoti & Co Operator Greetings and welcome to the Varex Imaging Corporation First Quarter Fiscal Year 2020 Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-K ____________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended September 27, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ______________________ ...

| --- | --- | --- | --- | |-------|-------|--------------------------------------------|-------| | | | A WORLD LEADER IN X-RAY IMAGING COMPONENTS | | | | | | | | | | September 2019 | 1 | | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2019 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ____________________________________________________________ FORM 10-Q ____________________________________________________________ Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37860 ____________ ...